LNAI

Lunai Bioworks is a pre-clinical, never-profitable biotech that in FY2025 explicitly disclosed 'substantial doubt about our ability to continue as a going concern.' The numbers corroborate the language starkly: the company has generated no sales revenue in its history, carries an accumulated deficit of $510M, and ended the year with just $92,700 of cash against $29.2M of current liabilities and $29.6M of total liabilities. Stockholders' equity is negative $21.3M, so book value is wiped out and the liabilities/equity ratio (-1.39x) is meaningless except as a signal of insolvency. Total assets collapsed 95% YoY to $8.23M. This is a balance sheet in distress, not a growth story.

The FY2025 loss of $178M (operating loss -$189M) reflects large impairments tied to real corporate failure: on September 2, 2025 the Court of Amsterdam declared subsidiary Gedi Cube B.V. bankrupt, forcing a material impairment. Meanwhile R&D — the only thing that could create value in a pre-clinical biotech — was slashed 80.2% to just $537K, meaning the company is starving its own pipeline to survive. Financing is desperate and punitive: $1.0M of promissory notes at 18% interest, additional notes at 10%, and a debt exchange in which $9.7M of secured notes were swapped for $16.1M of new convertible notes (a 65% premium) that immediately converted into 53.6M shares at $0.30. That single transaction illustrates the core risk to equity holders — relentless, deeply dilutive capital raises. Shares outstanding already grew 48.4% YoY to 232M, and the post-period conversions add more.